🚀 VC round data is live in beta, check it out!
Reviva Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Reviva Pharmaceuticals and similar public comparables like BioLineRx, Oncodesign Precision Medicine, Biomind Labs, Alzinova and more.
Reviva Pharmaceuticals Overview
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease and Parkinson’s disease psychosis and its other drug candidate is RP1208.
Founded
2018
HQ
Employees
14
Website
Sectors
Financials (LTM)
Market Cap
$11M
Reviva Pharmaceuticals Financials
Reviva Pharmaceuticals reported last 12-month revenue of —.
In the same LTM period, Reviva Pharmaceuticals generated had net loss of ($23M).
Revenue (LTM)
Reviva Pharmaceuticals P&L
In the most recent fiscal year, Reviva Pharmaceuticals reported revenue of — and EBITDA of ($20M).
Reviva Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($20M) | XXX | XXX | XXX |
| Net Profit | ($23M) | XXX | ($20M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Reviva Pharmaceuticals Stock Performance
Reviva Pharmaceuticals has current market cap of $11M.
Market Cap Evolution
Reviva Pharmaceuticals' stock price is $0.85.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $11M | 7.5% | XXX | XXX | XXX | $-1.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialReviva Pharmaceuticals Valuation Multiples
Reviva Pharmaceuticals trades at 0.2x EV/EBITDA.
Reviva Pharmaceuticals Financial Valuation Multiples
As of April 11, 2026, Reviva Pharmaceuticals has market cap of $11M.
Equity research analysts estimate Reviva Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Reviva Pharmaceuticals has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | ($3M) | XXX | ($3M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.2x | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Reviva Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Reviva Pharmaceuticals Margins & Growth Rates
Reviva Pharmaceuticals' revenue in the last fiscal year grew by —.
Reviva Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.4M for the same period.
Reviva Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (34%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Reviva Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioLineRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncodesign Precision Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Biomind Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Alzinova | XXX | XXX | XXX | XXX | XXX | XXX |
| CalciMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Reviva Pharmaceuticals M&A Activity
Reviva Pharmaceuticals acquired XXX companies to date.
Last acquisition by Reviva Pharmaceuticals was on XXXXXXXX, XXXXX. Reviva Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Reviva Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialReviva Pharmaceuticals Investment Activity
Reviva Pharmaceuticals invested in XXX companies to date.
Reviva Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Reviva Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Reviva Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Reviva Pharmaceuticals
| When was Reviva Pharmaceuticals founded? | Reviva Pharmaceuticals was founded in 2018. |
| Where is Reviva Pharmaceuticals headquartered? | Reviva Pharmaceuticals is headquartered in United States. |
| How many employees does Reviva Pharmaceuticals have? | As of today, Reviva Pharmaceuticals has over 14 employees. |
| Who is the CEO of Reviva Pharmaceuticals? | Reviva Pharmaceuticals' CEO is Laxminarayan Bhat. |
| Is Reviva Pharmaceuticals publicly listed? | Yes, Reviva Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Reviva Pharmaceuticals? | Reviva Pharmaceuticals trades under RVPH ticker. |
| When did Reviva Pharmaceuticals go public? | Reviva Pharmaceuticals went public in 2020. |
| Who are competitors of Reviva Pharmaceuticals? | Reviva Pharmaceuticals main competitors are BioLineRx, Oncodesign Precision Medicine, Biomind Labs, Alzinova. |
| What is the current market cap of Reviva Pharmaceuticals? | Reviva Pharmaceuticals' current market cap is $11M. |
| Is Reviva Pharmaceuticals profitable? | No, Reviva Pharmaceuticals is not profitable. |
| What is the current net income of Reviva Pharmaceuticals? | Reviva Pharmaceuticals' last 12 months net income is ($23M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.